Syndax to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 15, 2021

Rhea-AI Summary

Syndax Pharmaceuticals, Inc. (SNDX) will release its third quarter 2021 financial results on November 15, after U.S. market close. A conference call and live audio webcast will occur at 4:30 p.m. ET on the same day to discuss these results and provide a business update. The details for accessing the call are provided, including dial-in numbers and a link for the webcast. Syndax is focused on innovative cancer therapies, with a pipeline that includes SNDX-5613, axatilimab, and entinostat.

Positive

• Upcoming earnings release and conference call may indicate positive investor engagement.
• Continued development of innovative cancer therapies in the pipeline, potentially leading to future growth.

Negative

• None.

WALTHAM, Mass., Nov. 8, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its third quarter 2021 financial results on Monday, November 15, after the close of the U.S. financial markets.

In connection with the earnings release, Syndax's management team will host a conference call and live audio webcast at 4:30 p.m. ET on Monday, November 15, to discuss the Company's financial results and provide a general business update.

The live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company's website at www.syndax.com. Alternatively, the conference call may be accessed through the following:

Conference ID: 9558836
Domestic Dial-in Number: (855) 251-6663
International Dial-in Number: (281) 542-4259
Live webcast:  https://edge.media-server.com/mmc/p/85k2svad

For those unable to participate in the conference call or webcast, a replay will be available on the Investors section of the Company's website, www.syndax.com.

About Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. The Company's pipeline includes SNDX-5613, a highly selective inhibitor of the Menin–MLL binding interaction, axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor, and entinostat, a class I HDAC inhibitor. For more information, please visit www.syndax.com or follow the Company on Twitter and LinkedIn. 

Syndax Contacts

Investor Contact
Melissa Forst
Argot Partners
melissa@argotpartners.com
Tel 212.600.1902

Media Contact
Benjamin Kolinski
benjamin.kolinski@gcihealth.com
Tel 862.368.4464

SNDX-G

View original content:https://www.prnewswire.com/news-releases/syndax-to-announce-third-quarter-2021-financial-results-and-host-conference-call-and-webcast-on-november-15-2021-301418269.html

SOURCE Syndax Pharmaceuticals, Inc.

FAQ

When will Syndax Pharmaceuticals release its third quarter 2021 financial results?

Syndax Pharmaceuticals will release its third quarter 2021 financial results on November 15, 2021.

What time is the conference call for Syndax's earnings release?

The conference call for Syndax's earnings release is scheduled for 4:30 p.m. ET on November 15, 2021.

How can I access Syndax Pharmaceuticals' earnings conference call?

You can access the conference call by dialing (855) 251-6663 for domestic calls or (281) 542-4259 for international calls.

What is the main focus of Syndax Pharmaceuticals?

Syndax Pharmaceuticals is focused on developing innovative cancer therapies.